Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ProstAtak (aglatimagene besadenovec)
i
Other names:
AdV-tk therapy, gene mediated cytotoxic immunotherapy, TKR therapy, adeno-HSV-tk, Ad HSV-tk, adenovirus-mediated herpes simplex virus thymidine kinase gene therapy, CAN-2409
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(6)
News
Trials
Company:
Candel Therap
Drug class:
Gene transference, Thymidine kinase stimulant
Related drugs:
‹
quaratusugene ozeplasmid (3)
AdCD40L (0)
retroviral expression vectors bearing inhibitory genes (0)
E7 TCR cells (0)
GZ402663 (0)
LPX EWS/FL1 T1 (0)
EG-70 (0)
BC 819 (0)
rAAV2tYF-PR1.7-hCNGB3 (0)
GEN2 (0)
quaratusugene ozeplasmid (3)
AdCD40L (0)
retroviral expression vectors bearing inhibitory genes (0)
E7 TCR cells (0)
GZ402663 (0)
LPX EWS/FL1 T1 (0)
EG-70 (0)
BC 819 (0)
rAAV2tYF-PR1.7-hCNGB3 (0)
GEN2 (0)
›
Associations
(6)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
pembrolizumab + aglatimagene besadenovec
Sensitive: B - Late Trials
pembrolizumab + aglatimagene besadenovec
Sensitive
:
B
pembrolizumab + aglatimagene besadenovec
Sensitive: B - Late Trials
pembrolizumab + aglatimagene besadenovec
Sensitive
:
B
No biomarker
Pancreatic Ductal Adenocarcinoma
No biomarker
Pancreatic Ductal Adenocarcinoma
aglatimagene besadenovec
Sensitive: B - Late Trials
aglatimagene besadenovec
Sensitive
:
B
aglatimagene besadenovec
Sensitive: B - Late Trials
aglatimagene besadenovec
Sensitive
:
B
MGMT unmethylation
Glioma
MGMT unmethylation
Glioma
nivolumab + aglatimagene besadenovec
Sensitive: C3 – Early Trials
nivolumab + aglatimagene besadenovec
Sensitive
:
C3
nivolumab + aglatimagene besadenovec
Sensitive: C3 – Early Trials
nivolumab + aglatimagene besadenovec
Sensitive
:
C3
MGMT promoter methylation
Glioma
MGMT promoter methylation
Glioma
nivolumab + aglatimagene besadenovec
Sensitive: C3 – Early Trials
nivolumab + aglatimagene besadenovec
Sensitive
:
C3
nivolumab + aglatimagene besadenovec
Sensitive: C3 – Early Trials
nivolumab + aglatimagene besadenovec
Sensitive
:
C3
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
aglatimagene besadenovec
Sensitive: C3 – Early Trials
aglatimagene besadenovec
Sensitive
:
C3
aglatimagene besadenovec
Sensitive: C3 – Early Trials
aglatimagene besadenovec
Sensitive
:
C3
PD-L1 underexpression
Non Small Cell Lung Cancer
PD-L1 underexpression
Non Small Cell Lung Cancer
aglatimagene besadenovec
Sensitive: C3 – Early Trials
aglatimagene besadenovec
Sensitive
:
C3
aglatimagene besadenovec
Sensitive: C3 – Early Trials
aglatimagene besadenovec
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login